103 results about "Extended release" patented technology

An oral amphetamine extended release solid dose is described. The compositions contain a combination of an uncoated amphetamine-cation exchange resin complex, a barrier coated amphetamine-cation exchange resin complex-matrix, and an uncomplexed amphetamine, wherein one or more of these components contains blends of different forms of amphetamines. Either the modified release coated and / or the uncoated amphetamine-cation exchange resin complex may have two forms of amphetamine in a complex with a single cation exchange resin. Following administration of a single dose of the composition, a therapeutically effective amount of amphetamine is reached by about one hour and the composition provides at least a thirteen hour effect post-dose.

The invention relates to the technical field of bird repelling agents, in particular to a bird repelling agent based on thiocyanuric acid and a preparation method thereof, and the bird repelling agent is prepared from the following raw materials: thiocyanuric acid, modified beta-cyclodextrin, a magnetic powder synergist, a gel matrix, a synergistic aid, a solvent and a surfactant. The invention discloses a bird repellent based on thiocyanuric acid and a preparation method thereof, thiocyanuric acid is included through monoisocyanate modified beta-cyclodextrin, a magnetic powder synergist and a gel matrix are combined to form a'molecular inclusion-magnetic response-gel fixation 'triple-action system, and the problems that an existing bird repellent is short in time efficiency and poor in weather resistance are solved. The release time of the bird repellent is prolonged, the high bird repelling rate is still kept under the conditions of high temperature and rainwater, and the bird repellent is suitable for scenes such as farmlands and electric power facilities and has remarkable technical progress and practical value.

Provided herein are locoregional therapies using conjugates of therapeutic agents that demonstrate extended release of the native therapeutic agents, as well as methods for the manufacture of such conjugates. These conjugates may be useful in the treatment of various conditions and diseases that respond to the extended exposure to the therapeutic agents, or for delivery of therapeutic agents that suffer from undesired systemic toxicities. In certain embodiments, the locoregional therapy is intratumoral therapy, which may be combined with a systemic or local therapy for enhanced therapeutic efficacy and reduced toxicity of the combined agents.

Some embodiments of the present application are related to multivesicular liposome (MVL) formulations encapsulating dexamethasone or an ester or an ester salt thereof, for example, dexamethasone sodium phosphate (DSP) that may provide about 3-28 days extended release of dexamethasone. Processes of making and administering dexamethasone encapsulated multivesicular liposome formulations and their uses for treating pain or inflammation are also provided.

A nanoparticle-well treatment additive complex comprising an amine functionalized silica nanoparticle, and a well treatment additive, where the well treatment additive is releasably attached to an amine group of the amine functionalized silica nanoparticle is disclosed. Methods of using the amine functionalized silica nanoparticle is also disclosed.

The invention relates to pharmaceutical matrix tablets for oral administration comprising a bradykinin B2 receptor antagonist having a chemical structure according to Formula (1), or a salt or solvate thereof, wherein R is deuterium or hydrogen: Formula (1) such as (S)-1V-(1-deutero-1-(3-chloro-5-fluoro-2-((2-methyl-4-(1-methyl-1 / / -1,2,4-triazol-5-yl)quinolin-8-yloxy)methyl)phenyl)ethyl)-2-(difluoromethoxy)acetamide. The matrix tablets reliably provide extended release of the bradykinin B2 receptor antagonist which makes them particularly suitable for prophylactic and / or chronic therapies. Therapeutic uses of the matrix tablets are provided.

The present invention relates to a liquid nitric oxide releasing solution (NORS) comprised of at least one nitric oxide releasing compound and at least one acidifying agent, wherein the NORS provides an extended release of a therapeutically effective amount of nitric oxide gas (gNO). The present invention also relates to a liquid NORS comprised of at least one nitrite compound having a concentration of no greater than about 0.5% w / v and at least one acidifying agent, wherein the NORS releases a therapeutically effective amount of gNO. The present invention also relates to a method for the treatment of a wound in a human, the method comprising administering to the human a liquid NORS comprised of at least one nitric oxide releasing compound and at least one acidifying agent, wherein the NORS provides an extended release of a therapeutically effective amount of gNO. The present invention also relates to a method for the treatment, prevention, or reduction of incidence of a disease or disorder in a human in need thereof, the method comprising administering to the human a liquid NORS comprised of at least one nitrite compound at a concentration of no greater than about 0.5% w / v and at least one acidifying agent, wherein the NORS releases a therapeutically effective amount of gNO.

Disclosed herein are methods of treating or preventing inflammatory diseases of the gastrointestinal (GI) tract by topical administration of a pharmaceutical composition containing a delayed release composition formulated for extended release of corticosteroids into GI tissue.

The present disclosure provides dosage forms designed to deliver active pharmaceutical ingredients (APIs) in a controlled release manner. For instance, the present disclosure includes dosage forms with adequate time of onset of action and reduced lag times in the fed state. Such dosage forms find use in a variety of conditions where a rapid onset of action is desired followed by an extended release phase for the active agent, for example in the treatment of ADHD, pain or anxiety. In some cases, the dosage form includes a drug composition including a pharmacologically active agent, a barrier layer covering at least a portion of the drug composition, and a drug layer covering at least a portion of the barrier layer, wherein the drug layer includes the pharmacologically active agent. Related methods of making and administering the disclosed dosage forms are also provided.

Disclosed are a pharmaceutical composition comprising a compound of formula (I) as an active ingredient for inhibiting JAK, or treating JAK-mediated disease or disorder, a process for preparing the same and use of the same. The pharmaceutical composition has an advantage of high dissolution, and further has one or more advantages such as extended release, good pharmacokinetic properties.

Provided herein are methods of treating COVID-19 in a subject in need thereof, comprising administering to the subject a 25-hydroxyvitamin D compound. Also provided herein are hard capsule dosage forms of 25-hydroxyvitamin. In aspects, the 25-hydroxyvitamin D is administered as a controlled release formulation, optionally an extended release oral formulation, such as Rayaldee® extended release calcifediol capsules. Methods of treating SARS-CoV-2 infection including reducing SARS-CoV-2 viral load are provided. Methods of treating SARS-CoV-2 infection including increasing an immune response are provided.

Corticosteroid compositions including a corticosteroid drug substance (e.g., fluocinolone, fluocinolone acetonide, dexamethasone, dexamethasone phosphate, dexamethasone sodium phosphate, triamcinolone, and triamcinolone acetonide) or a or a salt or derivative thereof and one or more irregular-shaped particulate fatty acid or keto-enol tautomer complexation agents admixed in a dispersal medium, having a release profile with one or more phases of drug release. These compositions are extended release corticosteroid compositions may release a clinically useful level of corticosteroid for more than 1 to 12 months within the body. Also described herein are methods of forming and methods of using these compositions.

Extended-release formulation of metformin and berberine for long-lasting antidiabetic effects, comprehensive a) Metformin HCl in a quantity of 750 mg, b) Berberine HCl in an amount of 290 mg, c) Hydroxypropylmethylcellulose as the release-controlling polymer in an amount of 160 mg, d) Polyvinylpyrrolidone as a binder in an amount of 28 mg, e) microcrystalline cellulose as a filler in an amount of 170 mg, f) Magnesium stearate as a lubricant in an amount of 8 mg, g) colloidal silicon dioxide as a lubricant in an amount of 4 mg, h) Sodium stearyl fumarate as a lubricant in an amount of 6 mg, i) Talc as an anti-adhesive in an amount of 6 mg, wherein the composition is formulated for prolonged-release drug delivery to provide prolonged therapeutic effects in the treatment of diabetes mellitus.

The invention relates to the technical field of medical instruments, in particular to a targeted balloon coating capable of prolonging the release period in a dynamic environment and a preparation method of the targeted balloon coating. The renaturable xerogel can be quickly rehydrated after being dried, and a temporary membrane is formed on the inner wall of a blood vessel to resist blood flow scouring. The exosome enhances the vascular endothelium targeting through RGD peptide targeted modification. The polydopamine-hyaluronic acid composite adhesion coating improves the flexibility and adhesion of the coating. Therefore, the drug retention rate within 1 hour after expansion is greater than or equal to 85%, and the vascular endothelium uptake efficiency of the RGD modified exosome is improved by 3 times.

A nanoparticle for well-treatment applications and compositions and methods of making and using the same can include a carrier material and an asphaltene inhibitor. The asphaltene inhibitor is capable of being released from the carrier material. The nanoparticle can have a size of 10 nanometers (nm) to 500 nm.

Provided herein are polymer compositions and extended release otic agents. In one aspect, provided herein is a polymer composition including about 5% to about 15% by weight of the polymer composition of a functional polymer, wherein the functional polymer includes a first functional group, about 0.05% to about 0.6% by weight of the polymer composition of a crosslinker, wherein the crosslinker includes a second functional group, and water, wherein a crosslinking reaction can occur between the first functional group and the second functional group to form a gel, and wherein the polymer composition has a gelation time of about 45 seconds to about 60 minutes at a temperature of about 20° C.

A composition for oral administration of gamma aminobutyric acid (GABA), the composition comprising: GABA; at least one retention agent configured to increase retention of the composition, and the GABA contained in the composition, in the stomach for an extended period of time; and at least one slow release agent configured to allow extended release of the GABA from the composition. Additional embodiments of the composition, it method of administration and its use are disclosed herein.

The disclosure pertains to implantable medical devices for controlled delivery of therapeutic agents. Some devices according to the disclosure have a titanium reservoir, and a porous titanium oxide based membrane to control the rate of release of the therapeutic agent. The reservoir contains a formulation of the active agent, including a stabilizer for the active agent, wherein the stabilizer is provided in an extended-release configuration or a sustained release carrier.

The present invention provides injectable microsphere formulations comprising extended release of ketamine, and also provides methods of making and using the microsphere formulations.

Corticosteroid compositions including a corticosteroid drug substance (e.g., fluocinolone, fluocinolone acetonide, dexamethasone, dexamethasone phosphate, dexamethasone sodium phosphate, triamcinolone, and triamcinolone acetonide) or a or a salt or derivative thereof and one or more irregular-shaped particulate fatty acid or keto-enol tautomer complexation agents admixed in a dispersal medium, having a release profile with one or more phases of drug release. These compositions are extended release corticosteroid compositions may release a clinically useful level of corticosteroid for more than 1 to 12 months within the body. Also described herein are methods of forming and methods of using these compositions.

The present invention provides a liposomal pharmaceutical formulation for subcutaneous or intravenous administration of antibodies, comprising one or more phospholipids; one or more antibodies; and a pharmaceutically acceptable vehicle, wherein the one or more phospholipids form liposomes that encapsulate the one or more antibodies, wherein the liposomes have a polydispersity index (PDI) below 0.2 and at least 90% of the liposomes have a size less than 125 nm.

The invention relates to a nicotine chewing gum giving an immediate release and uptake of nicotine as well as an extended release and uptake of nicotine as well as describing suitable manufacturing processes for such chewing gum formulations and the use of the chewing gum for the treatment of a human being suffering from cravings from tobacco and / or e-cigarette dependency.

A dosage form of lacosamide and a pharmaceutical dosage form thereof is disclosed. The dosage form includes an extended release portion and an immediate release portion. Also provided are methods of providing extended release of lacosamide and treatment of a neurological or psychiatric disease or condition.

Aspects of the invention provide oral immediate release (IR) and / or extended release (ER) compositions comprising a therapeutically effective amount of aminodihydrophthalazinedione sodium (ADPS).

The present invention provides methods of treating patients with long acting injectable paliperidone palmitate formulations. The disclosure includes methods for mitigating at least one adverse change in blood lipid levels of a patient in need thereof who has been treated with a paliperidone palmitate extended-release injectable suspension at either one-month intervals (PP1M) or three-month intervals (PP3M), comprising transitioning the patient to a paliperidone palmitate extended-release injectable suspension having a six month dosing interval (PP6M).

We disclose here the nano-enabled delivery of highly potent 5-hydroxymethyl furfural (5-HMF) to sickled blood cells in patients. 5-HMF, a superior antisickling agent, has been formulated to address the limitations of existing treatment modalities arising from disfavorable pharmacokinetics of the drug compound. Specifically, two complementary 5-HMF prodrugs are integrated as a ‘protected’ biocompatible composite nanoparticle designed to readily fuse with RBCs and be amenable to transdermal delivery (5-HMF-grafted-phospholipid layered over a sucrose-derived graphitic carbon dot core). These RBC-targeted, protected, biocompatible, self-assembled 5-HMF prodrug nanoparticles for sickle cell disease are the first in class technology for offering a treatment for sickle cell disease which has improved potency, targeted payload delivery, and extended release with the red blood cells with enhanced pharmacodynamic effect in a treated patient.

The disclosure provides methods of treating opioid use disorder in a human by rapid induction with monthly injectable extended release buprenorphine, and to rapid induction dosage regimens for treating opioid use disorder. The methods provide increased treatment retention compared to standard of care methods.

The present invention relates to an injectable formulation, a method for treating a metabolic disease and an administration device. The injectable formulation comprises a lipid matrix composition, a specific amount of a GLP-1 receptor agonist and at least one pharmaceutically acceptable ion. Accordingly, upon contacting an aqueous fluid, the injectable formulation forms a depot exhibiting an extended release of the GLP-1 receptor agonist in vivo or in vitro. In the method for treating the metabolic disease, the injectable formulation can be administered to a subject with a reduced dosing frequency, and it is not necessary to store the injectable formulation for the next administration. For the administration device, the injectable formulation is filled in a vial, a pre-filled syringe or a pre-filled cartridge. Therefore, the injectable formulation can be designed for a single use, thereby enhancing convenience, compliance and adherence of a subject.

The present disclosure provides novel associated form (AF) of ketoprofen / dexketoprofen and lidocaine, and topical compositions thereof for use in topical products to treat patients with localized pain and inflammation. The novel ketoprofen / dexketoprofen and lidocaine AF acts as an extended-release drug delivery system due to extended release of the two drugs from the AF.

The present invention provides methods and kits for preventing, treating or delaying various cardiovascular diseases or disorders especially heart failure by extended release of neuregulin to a mammal. Moreover, the extended release of neuregulin is administered by subcutaneous infusion with a pump.